Cinclus Pharma

Cinclus Pharma (CINPHA) investor relations material

Cinclus Pharma Q4 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.

Q4 2025 earnings summary18 Feb, 2026

Executive summary

Linaprazan glurate, a next-generation P-CAB, targets severe erosive GERD with 24-hour acid control and blockbuster potential, addressing high unmet medical needs globally.
Phase III HEALING 1 trial underway, with first patient dosed in Q4 2025; topline results expected in H2 2026.
Strategic partnerships with Zentiva (Europe, up to €220m deal) and Sinorda (China) support commercialization and market access.
Regulatory progress includes positive FDA and EMA feedback on CMC and non-clinical plans, with no additional tox studies required for NDA submission.
China’s National Reimbursement Listing granted for linaprazan glurate, supporting a 2026 launch.

Financial highlights

Q4 2025 net sales: SEK 13.6 million, up from SEK 4.6 million in Q4 2024; full-year 2025 net sales: SEK 57.5 million, mainly from licensing income.
Operating loss for Q4 2025: SEK 62 million; full-year 2025 operating loss: TSEK -199,558, reflecting increased R&D spend.
Net loss for Q4 2025: SEK 61.2 million; full-year 2025 net loss: TSEK -183,972.
Cash at year-end 2025: SEK 487 million, supporting ongoing phase III activities.
R&D expenses for Q4 2025: SEK 61 million, representing 80% of total operating expenses.

Outlook and guidance

HEALING 1 phase III trial recruitment on track; topline results expected in H2 2026.
Second phase III healing and maintenance study planned, with maintenance phase expected to last 24 weeks and long-term safety follow-up for at least 52 weeks in 100 patients.
Anticipated China launch in 2026 following price and reimbursement approval.
€5m near-term milestone from Zentiva expected in 2026.
Financing is sufficient through H1 2027.

What is the HEEALING 2 study's planned scope?

How will US market potential be realized?

Post-HEEALING 1 readout, what is financing plan?

How to justify premium pricing for linaprazan glurate?

How will tegoprazan affect PCAB pricing dynamics?

Timing of Zentiva near-term milestone payment?

Partial view of Summaries dataset, powered by Quartr API

AI can get things wrong. Verify important information.

Research faster. Power your platform.

Latest events from Cinclus Pharma

View more events

Next Cinclus Pharma earnings date

Q1 202613 May, 2026

Companies

Cinclus Pharma

Your earnings  season toolkit.

Download

Free on both iOS & Android.

Next Cinclus Pharma earnings date

Q1 202613 May, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.

Leroy DaleyApp Store

One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.

Eferix Drawings Google Play

This is genuinely one of the cleanest and fastest finance apps out there to track the market.

anuj283App Store

Leroy DaleyApp Store

One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.

Eferix Drawings Google Play

This is genuinely one of the cleanest and fastest finance apps out there to track the market.

anuj283App Store

I can't remember the last time an app had such a positive impact on my investment process.

@ankurshah47_ x.com

Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.

Amina0781App Store

Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.

@theshortbearx.com

I can't remember the last time an app had such a positive impact on my investment process.

@ankurshah47_ x.com

Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.

Amina0781App Store

Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.

@theshortbearx.com

I’m actually shocked at just how much I like Quartr. If you’re an analyst & need a strong web tool + mobile app that syncs properly, saves you from manually dialing into calls.

@endthepods x.com

A must have for every investor. includes all quarterly reports with earnings calls and transcripts in single app

Abdulla AlnaamaGoogle Play